After Buying HUB and Partnering with Promega, MilliporeSigma Charts Growth Path in Organoids

Why It Matters

The expansion accelerates the commercialization of human‑derived organoids, offering drug developers more predictive preclinical data and reducing reliance on animal studies. This could shorten development timelines and lower costs across the biotech industry.

Key Takeaways

• MilliporeSigma bought HUB Organoids for €104M.
• Partnership with Promega adds real‑time organoid assay capabilities.
• FDA guidance encourages NAMs, boosting organoid adoption.
• Automation deals with Opentrons aim for higher throughput.
• Discovery Solutions unit now houses organoid portfolio.

Pulse Analysis

The organoid market is entering a rapid growth phase as pharmaceutical companies seek alternatives to animal testing and traditional 2D cultures. Human‑derived, three‑dimensional models provide a closer mimic of tissue architecture and disease biology, improving the predictive power of early‑stage drug screening. Recent FDA initiatives, such as the draft guidance on new approach methodologies, signal regulatory acceptance that is encouraging broader adoption of organoid platforms across biotech and academic labs.

MilliporeSigma’s strategy combines acquisition, partnership, and automation to capture this momentum. By purchasing HUB Organoids, the company secured a robust patent portfolio and a suite of ready‑to‑use models. The collaboration with Promega adds sophisticated, real‑time reporter assays that translate organoid biology into actionable data, while the Opentrons automation agreement reduces manual handling and boosts throughput. A parallel alliance with imec aims to integrate organoids with micro‑physiological systems, creating a seamless in‑vitro‑to‑in‑silico pipeline that can generate high‑quality training data for AI‑driven drug discovery.

These coordinated moves give MilliporeSigma a competitive edge in the emerging next‑generation biology space. Customers gain access to scalable, reproducible organoid services paired with automated assay workflows, shortening the path from target validation to IND filing. As more INDs, like SillaJen’s vascularized organoid‑based submission, demonstrate regulatory viability, the industry is likely to see a shift toward fully organoid‑driven preclinical programs, driving faster timelines, lower costs, and reduced ethical concerns associated with animal use.